Thomas Mair
Thomas Mair
M. Sc.
  • Working area 1
Languages
German (Mother tongue)
English

Publications

2024

Multiomic profiling of medulloblastoma reveals subtype-specific targetable alterations at the proteome and N-glycan level
Godbole S, Voß H, Gocke A, Schlumbohm S, Schumann Y, Peng B, Mynarek M, Rutkowski S, Dottermusch M, Dorostkar M, Korshunov A, Mair T, Pfister S, Kwiatkowski M, Hotze M, Neumann P, Hartmann C, Weis J, Liesche-Starnecker F, Guan Y, Moritz M, Siebels B, Struve N, Schlüter H, Schüller U, Krisp C, Neumann J
NAT COMMUN. 2024;15(1):6237.

The Histogenetic Origin of Malignant Cells Predicts Their Susceptibility towards Synthetic Lethality Utilizing the TK.007 System
Pallasch F, Freytag V, Kriegs M, Gatzemeier D, Mair T, Voss H, Riecken K, Dawood M, Fehse B, Efferth T, Schlüter H, Schumacher U
CANCERS. 2024;16(12):.

2023

Rhizochalinin Exhibits Anticancer Activity and Synergizes with EGFR Inhibitors in Glioblastoma In Vitro Models
Dyshlovoy S, Hauschild J, Venz S, Krisp C, Kolbe K, Zapf S, Heinemann S, Fita K, Shubina L, Makarieva T, Guzii A, Rohlfing T, Kaune M, Busenbender T, Mair T, Moritz M, Poverennaya E, Schlüter H, Serdyuk V, Stonik V, Dierlamm J, Bokemeyer C, Mohme M, Westphal M, Lamszus K, von Amsberg G, Maire C
MOL PHARMACEUT. 2023;20(10):4994-5005.

PKA mediates modality-specific modulation of the mechanically gated ion channel PIEZO2
Schaefer I, Verkest C, Vespermann L, Mair T, Voß H, Zeitzschel N, Lechner S
J BIOL CHEM. 2023;299(6):104782.

Letzte Aktualisierung aus dem FIS: 04.11.2024 - 03:41 Uhr